Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UTTR1147A open-label extension in ulcerative colitis or Crohn's disease
NL-OMON46443Phase 2Withdrawn
- Sponsor
- Genentech
- Start
- Dec 2018
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of efmarodocokin alfa in Crohn's disease and autoimmune colitis (2 arms), sponsored by Genentech. Primary endpoints: Occurrence and severity of adverse events and Change in vital signs, physical findings, and laboratory test results. Planned start Dec 2018; status: withdrawn.
02
Drugs
efmarodocokin alfa
03
Conditions
Crohn's diseaseautoimmune colitis
Beyond the preview
Go deeper on NL-OMON46443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46443.